Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
Vascular endothelial growth factor (VEGF) is essential in the pathogenesis of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). As such, VEGF inhibitors have become commonly used and effective pharmacologic strategies for both diseases. However, limitations exist, such as co-payments and the need for in-person clinical visits and multiple intravitreal injections each year. New therapies are emerging to address these limitations by improving the durability of treatment response to decrease treatment burden.
In this program, expert faculty discuss the role of VEGF in the pathogenesis of nAMD and DME, review recent clinical trial data for VEGF inhibitors, and examine the potential of novel therapies as future treatment options.
This educational activity is an archive of the live virtual symposium held on July 31, 2025.
Target Audience
This educational activity is directed toward retina specialists and comprehensive ophthalmologists who would be involved in the management of patients with neovascular retinal diseases such as nAMD and DME who might be treated with VEGF inhibitors.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the role of VEGF in the pathogenesis of nAMD and DME
- Describe the mechanism of action of novel therapies that target VEGF
- Assess current evidence evaluating the role of VEGF inhibitors in the treatment of nAMD and DME
- Identify patients appropriate for treatment with VEGF inhibitors based on clinical presentation and goals of therapy
David Almeida, MD, PhD, MBA
Investigator in Chief
Erie Retina Research
Vitreoretinal Surgeon and Clinician Scientist
The Centers for Advanced Surgical Exploration
Erie, PA
Disclosures: Researcher: Acelyrin, Alcon, Alimera Sciences, Allergan/AbbVie, Alumis, Boehringer Ingelheim, Dutch Ophthalmics, EyePoint Pharmaceuticals, Genentech, Novartis, Opthea, Regeneron, Regenxbio, Roche; Consultant Researcher: Dutch Ophthalmics, EyePoint Pharmaceuticals, Novartis, Opthea, Regeneron, Regenxbio; Consultant: Acelyrin, Alcon, Alimera Sciences, Allergan/AbbVie, Alumis, Boehringer Ingelheim, Dutch Ophthalmics, EyePoint Pharmaceuticals, Genentech, Novartis, Opthea, Regeneron, Regenxbio, Roche.
Margaret A. Chang, MD, MS
Senior Partner
Retinal Consultants Medical Group
Sacramento, CA
Disclosures: Speaker: Genentech; Consultant: AbbVie/Regenxbio, Astellas, Boehringer Ingelheim, Eyepoint Pharmaceuticals, Genentech, Ocular Therapeutix, Oculis, Ollin Biosciences, Opthea, Outlook Therapeutics, Zeiss; Research Support: 4DMT, Adverum Biotechnologies, Alexion, EyeBio, Kodiak Sciences, Mylan, NGM, Novartis, OcuTerra, Outlook Therapeutics, Perceive; Stock Options: Ollin Biosciences.
Arshad M. Khanani, MD, MA, FASRS
Clinical Professor
School of Medicine
University of Nevada, Reno
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Reno, NV
Disclosures: Consultant: 4DMT, AbbVie, Adverum, Alcon, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Aviceda Therapeutics, Beacon Therapeutics, Boehringer Ingelheim, Clearside Biomedical, Complement Therapeutics, Exegenesis Bio, EyePoint Pharmaceuticals, Frontera Therapeutics, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Iveric Bio, Janssen Pharmaceuticals, Kodiak Sciences, Kriya Therapeutics, Kyowa Kirin, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olive BioPharma, Opthea, Oxular, Oxurion, Perfuse, Ray Therapeutics, Recens Medical, Regeneron Pharmaceuticals, Regenxbio, Revive, RevOpsis, Roche, Sanofi, Stealth BioTherapeutics, Thea Pharma, Unity Biotechnology, Vanotech, Vial; Research Support: 4DMT, Adverum, Alexion, Annexon, Apellis Pharmaceuticals, Aviceda Therapeutics, Eluminex Biosciences, EyePoint Pharmaceuticals, Exegenesis, Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen, Kodiak, Kyowa Kirin, Neurotech, Ocular Therapeutix, Oxular, Regenxbio; Stock Options: Aviceda Therapeutics, Oculis, Opthea, Perfuse Therapeutics, PolyPhotonix, Recens Medical, RevOpsis, Vial; Board of Directors: Oculis.
Jessica Randolph, MD
Associate Professor
School of Medicine
Department of Ophthalmology
Virginia Commonwealth University
Richmond, VA
Disclosures: Advisory Board: AbbVie, Genentech; Data Safety Monitoring Board: Astellas; Speaker’s Bureau: Apellis Pharmaceuticals.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here